Sun Pharma signs JV with Intrexon Corporation
The JV with the US based firm is to develop gene therapies.
Mumbai, October 2, 2013: Sun Pharma has signed a joint venture (JV) agreement with the US based Intrexon Corporation to develop controllable gene based therapies for the treatment of eye diseases. The 50:50 JV aims to leverage Sun Pharma’s global capabilities and experience in developing and manufacturing complex dosage forms and speciality pharmaceuticals for niche therapy areas.
The two companies are initially targeting age related macular degeneration, a medical condition that causes partial or full loss of vision among older adults; glaucoma, a kind of eye disease; and retinitis pigmentosa, an eye disease that causes severe vision loss and at times even blindness.